Profile data is unavailable for this security.
About the company
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
- Revenue in USD (TTM)0.00
- Net income in USD-143.54m
- Incorporated2016
- Employees85.00
- LocationCullinan Therapeutics IncOne Main Street, Suite 1350CAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 410-4650
- Fax+1 (302) 655-5049
- Websitehttps://cullinantherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | 57.17m | -165.66m | 644.18m | 117.00 | -- | 7.64 | -- | 11.27 | -6.07 | -6.07 | 2.09 | 2.77 | 0.1166 | -- | 7.39 | 488,649.60 | -33.78 | -18.08 | -36.91 | -18.96 | -- | -- | -289.75 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Adaptive Biotechnologies Corp | 177.28m | -195.24m | 644.92m | 709.00 | -- | 2.88 | -- | 3.64 | -1.34 | -1.34 | 1.21 | 1.52 | 0.2778 | 4.68 | 4.92 | 250,045.10 | -30.61 | -19.69 | -35.66 | -22.06 | 58.46 | 67.18 | -110.19 | -122.27 | 3.38 | -- | 0.3725 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Arbutus Biopharma Corp | 6.74m | -76.70m | 655.64m | 73.00 | -- | 6.13 | -- | 97.25 | -0.4259 | -0.4259 | 0.0374 | 0.5643 | 0.0451 | -- | 3.57 | 92,356.16 | -51.29 | -52.62 | -59.50 | -58.11 | -- | -- | -1,137.65 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| BIOAGE Labs Inc | 0.00 | -62.16m | 661.05m | 58.00 | -- | -- | -- | -- | -1.82 | -1.82 | 0.00 | 4.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.99 | 0.0724 | -- | -- | -- | -60.75 | -- | -- | -- |
| Tectonic Therapeutic Inc | 0.00 | -54.39m | 661.43m | 13.00 | -- | 4.40 | -- | -- | -13.91 | -13.91 | 0.00 | 10.20 | 0.00 | -- | -- | 0.00 | -38.96 | -45.22 | -42.77 | -49.14 | -- | -- | -- | -- | -- | -- | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Entrada Therapeutics Inc | 215.23m | 54.95m | 675.43m | 177.00 | 11.32 | 1.60 | 11.55 | 3.14 | 1.59 | 1.59 | 5.97 | 11.30 | 0.4141 | -- | 56.43 | 1,353,660.00 | 10.57 | -- | 13.68 | -- | -- | -- | 25.53 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -143.54m | 711.54m | 85.00 | -- | 1.13 | -- | -- | -2.88 | -2.88 | 0.00 | 10.80 | 0.00 | -- | -- | 0.00 | -25.35 | -12.37 | -26.45 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Oruka Therapeutics Inc | 0.00 | -7.20m | 717.47m | 4.00 | -- | 0.7608 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -154.14m | 722.08m | 116.00 | -- | 1.80 | -- | -- | -3.43 | -3.43 | 0.00 | 8.72 | 0.00 | -- | -- | 0.00 | -57.80 | -- | -65.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Erasca Inc | 0.00 | -159.12m | 734.51m | 126.00 | -- | 1.63 | -- | -- | -0.8294 | -0.8294 | 0.00 | 1.59 | 0.00 | -- | -- | 0.00 | -33.56 | -- | -35.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -213.02m | 754.95m | 331.00 | -- | 1.98 | -- | -- | -3.05 | -3.05 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -40.17 | -29.08 | -43.61 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1577 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Anavex Life Sciences Corp | 0.00 | -41.53m | 764.86m | 40.00 | -- | 5.89 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Prothena Corporation PLC | 133.35m | -131.83m | 776.59m | 173.00 | -- | 1.45 | -- | 5.82 | -2.48 | -2.48 | 2.47 | 9.93 | 0.1987 | -- | 51.70 | 770,809.30 | -19.64 | -14.20 | -21.22 | -15.11 | -- | -- | -98.86 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Relay Therapeutics Inc | 10.01m | -345.20m | 776.66m | 294.00 | -- | 0.9231 | -- | 77.62 | -2.61 | -2.61 | 0.076 | 5.03 | 0.0109 | -- | -- | 30,978.33 | -37.58 | -28.55 | -39.69 | -29.54 | -- | -- | -3,449.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Tyra Biosciences Inc | 0.00 | -83.74m | 777.26m | 49.00 | -- | 2.24 | -- | -- | -1.61 | -1.61 | 0.00 | 6.85 | 0.00 | -- | -- | 0.00 | -27.06 | -- | -28.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Cullinan Therapeutics Inc's reporting currency: US Dollar USD
45.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Sep 2024 | 5.75m | 9.92% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.89m | 6.70% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.88m | 4.96% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.34m | 4.03% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2024 | 2.32m | 4.00% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 2.17m | 3.75% |
| Citadel Advisors LLCas of 30 Sep 2024 | 1.96m | 3.37% |
| AllianceBernstein LPas of 30 Sep 2024 | 1.85m | 3.20% |
| RTW Investments LPas of 30 Sep 2024 | 1.71m | 2.94% |
| Holocene Advisors, LPas of 30 Sep 2024 | 1.53m | 2.65% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
